Olema appoints Scott Garland to Board; brings commercial expertise for late-stage palazestrant development

Olema Pharmaceuticals, Inc.

Scott Garland appointed to Board as Class III director effective Oct 16, 2023; term through 2026 annual meeting.
Received initial equity: options for 21,520 shares (3-year vest) and 14,347 shares (vests by 2024 annual meeting).
Annual cash retainer $40,000 plus $6,000 for Compensation Committee service; standard indemnification agreement.
Garland formerly CEO of Portola (led Andexxa launch and Alexion acquisition) and held senior roles at Exelixis, Genentech, Amgen.
Company highlights his commercial leadership as palazestrant advances to Phase 3 for breast cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.